AzTrials
AzTrials

Myocardial InfarctionPhase 3MINTNCT02981407

Myocardial Ischemia and Transfusion

A Phase 3 study testing Red Blood Cell Transfusion in people with Myocardial Infarction and Anemia, run by Rutgers, The State University of New Jersey at 133 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Myocardial Infarction, Anemia
What is being tested?
Red Blood Cell Transfusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,506 participants
Where
133 sitesin 6 countries
Study dates
25 Apr 2017to 20 Oct 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years of age or older
  • Either ST segment elevation myocardial infarction or Non ST segment elevation myocardial infarction consistent with the 3rd Universal Definition of Myocardial Infarction criteria that occurs on admission or during the index hospitalization
  • Hemoglobin concentration less than 10 g/dL at the time of random allocation
  • Patient physician believes that both of the transfusion strategies are consistent with good medical care for the patient

Who cannot join

  • Uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood
  • Decline blood transfusion
  • Scheduled for cardiac surgery during the current admission
  • Receiving only palliative treatment
  • Known that follow-up will not be possible at 30 days
  • Previously participated in MINT
  • Currently enrolled in a competing study that interferes with the intervention or follow-up of MINT or enrolled in a competing study that has not been approved by the local Institutional Review Board
  • Patient physician does not believe the patient is an appropriate candidate for the trial

Trial locations and contacts

133 sites in 6 countries.

133 sites in 6 countries

United States60 sites

  • Albany Medical College

    Albany, New York, 12208

  • University of New Mexico

    Albuquerque, New Mexico, 87131

  • University of Michigan

    Ann Arbor, Michigan, 48109

  • Southside Hospital

    Bay Shore, New York, 11706

  • Massachusetts General Hospital

    Boston, Massachusetts, 01930

  • Boston Medical Center

    Boston, Massachusetts, 02118

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 15261

  • NYP Brooklyn Methodist

    Brooklyn, New York, 11215

  • Lahey Hospital

    Burlington, Massachusetts, 01805

  • University of Vermont Medical Center

    Burlington, Vermont, 05401

  • Copper University Hospital

    Camden, New Jersey, 08103

  • Aultman Hospital

    Canton, Ohio, 44710

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599-7097

  • Rush University Medical Center

    Chicago, Illinois, 60612

  • University of Chicago Medical Center

    Chicago, Illinois, 60637

  • Danbury Hospital

    Danbury, Connecticut, 06810

  • Essentia Health

    Duluth, Minnesota, 55805

  • Durham Va

    Durham, North Carolina, 27705

  • Alexian Brothers Medical Center

    Elk Grove Village, Illinois, 60007

  • New York Presbyterian/Queens

    Flushing, New York, 11355

  • Greenville Health System

    Greenville, South Carolina, 29605

  • Memorial Hospital at Gulfport

    Gulfport, Mississippi, 39502

  • Hackensacjk University Medical Center

    Hackensack, New Jersey, 07601

  • Westchester Medical Center

    Hawthorne, New York, 10532

  • AMITA Health

    Hinsdale, Illinois, 60521

  • Baylor St Luke's Medical Center

    Houston, Texas, 77030

  • Saint Luke's Mid America Heart

    Kansas City, Kansas, 64111

  • Lancaster General Hospital

    Lancaster, Pennsylvania, 17602

  • Central Arkansas Veterans Healthcare System

    Little Rock, Arkansas, 72205

  • University of Arkansas Medical Sciences (UAMS) Hospital

    Little Rock, Arkansas, 72205

  • VAGLAHS

    Los Angeles, California, 90073

  • University of Louisville

    Louisville, Kentucky, 40202

  • North Shore University Hospital

    Manhasset, New York, 11030

  • The Memphis VAMC

    Memphis, Tennessee, 38104

  • Medical College of Wisconsin - Froedtert Hospital

    Milwaukee, Wisconsin, 53226

  • University of Minnesota Medical Center Fairview

    Minneapolis, Minnesota, 55105

  • Minneapolis Heart Institute (Foundation)

    Minneapolis, Minnesota, 55407-1130

  • Northern Westchester Hospital

    Mount Kisco, New York, 10549

  • Jersey Shore University Medical

    Neptune City, New Jersey, 08759

  • Robert Wood Johnson University Hospital

    New Brunswick, New Jersey, 08903

  • Tulane University School of Medicine

    New Orleans, Louisiana, 70112

  • NYU Langone Medical Center, Bellevue Hospital

    New York, New York, 10016

  • Lenox Hilll Hospital

    New York, New York, 10075

  • PENN Presbyterian Medical Cente

    Philadelphia, Pennsylvania, 19104

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15261

  • Rhode Island Hospital

    Providence, Rhode Island, 02903

  • The Miriam Hospital

    Providence, Rhode Island, 02906

  • WakeMed Health and Hospital

    Raleigh, North Carolina, 27610

  • Virginia Commonwealth University

    Richmond, Virginia, 23298

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • Rochester General Hospital

    Rochester, New York, 14450

  • University of Rochester

    Rochester, New York, 14642

  • Washington University

    St Louis, Missouri, 63110

  • Northwell Staten Island Hopsital

    Staten Island, New York, 10305

  • Stony Brook Medicine

    Stony Brook, New York, 11794-8167

  • Montefiore Medical Center

    The Bronx, New York, 10467

  • University of Toledo Medical Center

    Toledo, Ohio, 43614

  • Lankenau Medical Center

    Wynnewood, Pennsylvania, 19096

  • St. Joseph Mercy Health System

    Ypsilanti, Michigan, 48197

Other trials in United States

Canada27 sites

  • Foothills Medical Centre

    Calgary, Alberta

  • Grey Nuns Community Hospital

    Edmonton, Alberta

  • Royal Alexandra Hospital

    Edmonton, Alberta

  • University of Alberta Hospital

    Edmonton, Alberta

  • Hôpital Charles Lemoyne

    Greenfield Park, Quebec

  • QE II Health Sciences Center

    Halifax, Nova Scotia

  • Hamilton Health Sciences

    Hamilton, Ontario

  • Hamilton St. Joseph's Health

    Hamilton, Ontario

  • St. Joseph's Health Centre

    Hamilton, Ontario

  • Hotel-Dieu de Levis

    Lévis, Quebec

  • University Hospital - LHSC

    London, Ontario

  • Victoria Hospital - LHSC

    London, Ontario

  • Centre Hosp. Universitaire de Montréal

    Montreal, Quebec

  • Jewish General Hospital

    Montreal, Quebec

  • Montreal General Hospital

    Montreal, Quebec

  • Royal Victoria Hospital

    Montreal, Quebec

  • Royal Columbian Hospital

    New Westminster, British Columbia

  • Quebec Heart and Lung Institute

    Québec, Quebec

  • Regina General Hospital

    Regina, Saskatchewan

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Quebec

  • Surrey Memorial Hospital

    Surrey, British Columbia

  • St. Michael's Hospital

    Toronto, Ontario

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario

  • General Hospital Trois-Rivièrs

    Trois-Rivières, Quebec

  • Vancouver General Hospital

    Vancouver, British Columbia

  • Victoria Heart Institute

    Victoria, Ontario

  • St. Boniface General Hospital

    Winnipeg, Manitoba

Other trials in Canada

Brazil18 sites

  • Hospital Felício Rocho

    Belo Horizonte

  • Instituto Orizonti

    Belo Horizonte

  • Instituto de Ensino e Pesquisa do Hospital do Coração do Brasil

    Brasília

  • Hospital Vera Cruz

    Campinas

  • Santa Casa de Marília

    Cascata, 17515-900

  • Sociedade Hospitalar Angelina Caron

    Centro, 83430-000

  • Instituto de Ensino e Pesquisa do Hospital da Bahia

    Pituba, Salvador, 41810

  • Hospital Maternidade e Pronto Socorro Santa Lúcia

    Poços de Caldas

  • Instituto de Cardiologia do RS

    Porto Alegre

  • Hospital Agamenon Magalhães

    Recife

  • Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares- PROCAPE

    Recife

  • Hospital Cárdio Pulmonar

    Salvador

  • Hospital Universitário Professor Edgard Santos

    Salvador

  • Hospital de Base de Rio Preto

    São José do Rio Preto, São Paulo, 15080-310

  • Hospital de Base de Rio Preto

    São José do Rio Preto

  • Hospital São Paulo

    São Paulo, 04024-002

  • Hospital de Clínicas da UFTM

    Uberaba

  • Hospital das Clinicas da UFU

    Uberlândia

Other trials in Brazil

France18 sites

  • CHRU Tours -Hôpital Trousseau

    Chambray-lès-Tours

  • CH Chartres - Chartres

    Chartres

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes

  • CHU le Bocage - Dijon

    Dijon, 21079

  • La Tronche Hôpital Michallon

    La Tronche

  • Centre Hospitalier Universitaire de Lille

    Lille, 59000

  • CHU Arnaud de Villeneuve - Montpellier

    Montpellier

  • CHU Nancy

    Nancy

  • Hôpital Pasteur

    Nice, 06000

  • Hôpital Universitaire Carémeau (CHU Carémeau)

    Nîmes, 30029

  • Hôpital La Pitié Salpétrière

    Paris, 75013

  • Hôpital Européen Georges-Pompidou

    Paris, 75015

  • Hôpital BICHAT- APHP

    Paris, 75018

  • Hôpital Lariboisière

    Paris

  • Hôpital Haut Lévêque

    Pessac, 33604

  • CHU Poitiers - Poitiers

    Poitiers

  • Hôpital Charles Nicolle- Rouen

    Rouen

  • Hôpital Rangueil

    Toulouse, 31400

Other trials in France

New Zealand6 sites

  • Auckland City Hospital

    Auckland

  • Christchurch Hospital

    Christchurch

  • Gisborne Hospital

    Gisborne

  • Nelson Hospital

    Nelson

  • Taranaki Hospital

    New Plymouth

  • Whangarei Hospital

    Whangarei

Other trials in New Zealand

Australia4 sites

  • Flinders Medical Centre

    Bedford Park

  • Concord Repatriation General Hospital

    Concord

  • Gosford Hospital

    Gosford

  • Royal Perth Hospital

    Perth

Other trials in Australia

About this study

The purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic.

Read the detailed description

In most clinical settings, evidence suggests it is safe to wait to give a blood transfusion. However, for those who have suffered a heart attack, there is a lack of high quality evidence to guide transfusions. This 3500 subject multi-center randomized trial will fill that void.

Hospital inpatients diagnosed with myocardial infarction who have blood counts less than 10 g/dL are randomized to receive either a liberal or a restrictive transfusion strategy.

Patients randomized to the liberal transfusion strategy will receive a red blood cell transfusion anytime there is a blood count of less than 10 g/dL.

Patients randomized to the restrictive transfusion strategy are permitted to receive a blood transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion is ordered regardless of the blood count.

The transfusions strategies will be maintained until hospital discharge for a maximum of 30 days.

Patients will be followed for 30 days for clinically relevant outcomes. Vital status will be confirmed at 180 days.

Being tested
Red Blood Cell Transfusion
Keywords
Red Blood Cell Transfusion, Anemia, Heart Disease, Cardiovascular Disease
Medical subject headings
Myocardial Infarction, Anemia, Heart Diseases, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Red Blood Cell TransfusionBiological

    Transfusion of packed red blood cell units

Study groups in NCT02981407
Study groupRoleWhat they receive
Liberal Transfusion StrategyActive comparatorRed blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
Receives: Biological: Red Blood Cell Transfusion
Restrictive Transfusion StrategyActive comparatorPermitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
Receives: Biological: Red Blood Cell Transfusion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction

    Measured: Within 30 days of randomization

Secondary outcomes (3)

  1. All-cause Mortality

    Measured: Within 30 days of randomization

  2. Myocardial Reinfarction

    Measured: Within 30 days of randomization

  3. Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis

    Measured: Within 30 days of randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2016 (estimated)
  2. Study start25 Apr 2017
  3. Primary completion31 May 2023
  4. Study completion20 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
3,506 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02981407
Sponsor's protocol ID
Pro20160000722
Other IDs
1U01HL133817-01
Acronym
MINT
Status last verified
Apr 2024
First submitted
1 Dec 2016
Last updated
9 May 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Limited access data (i.e., records without personal identifiers) will be prepared by the Data Coordinating Center (DCC) and sent to the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) within 3 years after the end of the final patient follow-up or 2 years after the main paper of the trial has been published, whichever comes first. The Trial data set will include baseline patient characteristics, follow-up status, and clinical outcome data. The data will be released to requesting institutions and investigators in accordance with BioLINCC policy.

Publications

  • Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, Srinivas V, Menegus MA, Marroquin OC, Rao SV, Noveck H, Passano E, Hardison RM, Smitherman T, Vagaonescu T, Wimmer NJ, Williams DO. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013 Jun;165(6):964-971.e1. doi: 10.1016/j.ahj.2013.03.001. Epub 2013 Apr 8.

    PubMed 23708168

  • Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N, Ramsey G, Rao SV, Roback JD, Shander A, Tobian AA. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016 Nov 15;316(19):2025-2035. doi: 10.1001/jama.2016.9185.

    PubMed 27732721

  • Carson JL, Brooks MM, Chaitman BR, Alexander JH, Goodman SG, Bertolet M, Abbott JD, Cooper HA, Rao SV, Triulzi DJ, Fergusson DA, Kostis WJ, Noveck H, Simon T, Steg PG, DeFilippis AP, Goldsweig AM, Lopes RD, White H, Alsweiler C, Morton E, Hebert PC; MINT Investigators. Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial. Am Heart J. 2023 Mar;257:120-129. doi: 10.1016/j.ahj.2022.11.015. Epub 2022 Nov 20.

    PubMed 36417955

  • Carson JL, Brooks MM, Hebert PC, Goodman SG, Bertolet M, Glynn SA, Chaitman BR, Simon T, Lopes RD, Goldsweig AM, DeFilippis AP, Abbott JD, Potter BJ, Carrier FM, Rao SV, Cooper HA, Ghafghazi S, Fergusson DA, Kostis WJ, Noveck H, Kim S, Tessalee M, Ducrocq G, de Barros E Silva PGM, Triulzi DJ, Alsweiler C, Menegus MA, Neary JD, Uhl L, Strom JB, Fordyce CB, Ferrari E, Silvain J, Wood FO, Daneault B, Polonsky TS, Senaratne M, Puymirat E, Bouleti C, Lattuca B, White HD, Kelsey SF, Steg PG, Alexander JH; MINT Investigators. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia. N Engl J Med. 2023 Dec 28;389(26):2446-2456. doi: 10.1056/NEJMoa2307983. Epub 2023 Nov 11.

    PubMed 37952133

  • Kim S, Bertolet M, Chaitman BR, Alexander JH, Steg PG, Lopes RD, Simon T, Goodman SG, Strom JB, de Barros E Silva PGM, Ducrocq G, DeFilippis AP, Brooks MM, Carson J; MINT Trial investigators. Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial. Am Heart J. 2026 Aug 9:107553. doi: 10.1016/j.ahj.2026.107553. Online ahead of print.

    PubMed 42571785

  • Bertolet M, Carrier FM, Glynn S, Abbott JD, Defilippis AP, Simon T, Fordyce CB, Senaratne J, Potter BJ, Herbert BM, Rao SV, Caixeta A, Tessalee M, Cooper HA, Beraldo de Andrade P, Dall'Orto FTC, Silvain J, Carson JL, Brooks MM; Myocardial Ischemia and Transfusion (MINT) Trial Investigators. Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial. JAMA Netw Open. 2026 Jul 1;9(7):e2624991. doi: 10.1001/jamanetworkopen.2026.24991.

    PubMed 42507445

  • DeFilippis AP, Abbott JD, Herbert BM, Bertolet MH, Chaitman BR, White HD, Goldsweig AM, Polonsky TS, Gupta R, Alsweiler C, Silvain J, de Barros E Silva PGM, Hillis GS, Daneault B, Tessalee M, Menegus MA, Rao SV, Lopes RD, Hebert PC, Alexander JH, Brooks MM, Carson JL, Goodman SG; MINT Investigators. The Effect of Restrictive vs Liberal Blood Transfusion Strategy on Subsequent Myocardial Infarction Type. JACC Adv. 2026 Jun;5(6 Pt 2):102836. doi: 10.1016/j.jacadv.2026.102836.

    PubMed 42312774

  • Cooper HA, Fordyce CB, Herbert BM, Alexander JH, Rao SV, Brooks MM, Bertolet M, Carson JL, Hebert PC; Myocardial Ischemia and Transfusion (MINT) Trial Investigators. Red Cell Transfusion in Critically Ill and Noncritically Ill Patients With Acute Myocardial Infarction and Anemia-A Subanalysis of the Myocardial Ischemia and Transfusion (MINT) Trial. Crit Care Med. 2026 Sep 1;54(9):2430-2435. doi: 10.1097/CCM.0000000000007211. Epub 2026 May 27.

    PubMed 42188994

  • Abbott JD, Benatar JR, Ballantyne CM, Jacobs AK, Goldsweig AM, Fergusson DA, Hebert BM, Bertolet M, Simon T, Steg PG, Goodman SG, White HD, Carson JL, Brooks MM; MINT Investigators. Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial. Circulation. 2026 Jul 21;154(3):201-211. doi: 10.1161/CIRCULATIONAHA.125.078320. Epub 2026 May 18.

    PubMed 42145087

  • Goldsweig AM, Ballantyne CM, White HD, Abbott JD, Fergusson DA, Herbert BM, Goodman SG, Carson JL, Brooks MM; MINT Investigators. Effect of age on restrictive and liberal transfusion outcomes in patients with anemia and myocardial infarction. Am Heart J. 2026 Jul;297:107381. doi: 10.1016/j.ahj.2026.107381. Epub 2026 Feb 19.

    PubMed 41722885

  • Carson JL, Stanworth SJ, Dennis JA, Fergusson DA, Pagano MB, Roubinian NH, Turgeon AF, Valentine S, Trivella M, Doree C, Hebert PC. Transfusion thresholds and other strategies for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2025 Oct 20;10(10):CD002042. doi: 10.1002/14651858.CD002042.pub6.

    PubMed 41114449

  • Prochaska MT, Portela GT, Brooks MM, Fergusson DA, Hebert PC, Polonsky TS, Caixeta A, Cooper HA, Crozier I, Daneault B, Kim S, Bainey KR, de Barros E Silva P, Goldfarb M, Gupta R, Rao SV, Fonteles Ritt LE, Simon T, Carson JL. Transfusion Strategy Effect on Quality of Life in Patients With Myocardial Infarction and Anemia: A Secondary Analysis of the MINT Randomized Clinical Trial. JAMA Intern Med. 2025 Aug 1;185(8):947-954. doi: 10.1001/jamainternmed.2025.0654.

    PubMed 40459491

  • Rao SV, Brooks MM, D'Agostino HEA, Steg PG, Simon T, Aronow HD, Goldsweig AM, Malik S, Alsweiler C, Ho KKL, Dehghani P, Caixeta A, Quraishi AR, Robinson S, Traverse JH, Siddiqi O, Fergusson DA, Potter BJ, Schulman-Marcus J, Keating FK, Carson JL; MINT Trial Investigators. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial. Circ Cardiovasc Interv. 2025 May;18(5):e015249. doi: 10.1161/CIRCINTERVENTIONS.125.015249. Epub 2025 Mar 30.

    PubMed 40159118

  • Goldsweig AM, Kostis WJ, Herbert BM, Bouleti C, Potter BJ, Strom JB, Benatar J, Huynh T, Vallurupalli S, Figueiredo EL, Abbott JD, Cooper HA, DeFilippis AP, Fergusson DA, Goodman SG, Hebert PC, Lopes RD, Rao SV, Simon T, Carson JL, Brooks MM, Alexander JH; MINT Investigators. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT. Circ Heart Fail. 2025 Apr;18(4):e012495. doi: 10.1161/CIRCHEARTFAILURE.124.012495. Epub 2025 Mar 26.

    PubMed 40135329

  • Portela GT, Ducrocq G, Bertolet M, Alexander JH, Goodman SG, Glynn S, Strom JB, Swanson SA, Lemesle G, Rao SV, Tessalee M, Polonsky TS, Goldfarb M, Traverse JH, Uhl L, Herbert BM, Silvain J, Carson JL, Brooks MM; MINT Trial Investigators. Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia. Am Heart J. 2025 Apr;282:146-155. doi: 10.1016/j.ahj.2025.01.009. Epub 2025 Jan 17.

    PubMed 39826701

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Red Blood Cell Transfusion in people with Myocardial Infarction and Anemia, run by Rutgers, The State University of New Jersey at 133 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 133 sites in United States, Canada, Brazil, France, New Zealand and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction (time frame: Within 30 days of randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02981407, which also lists 21 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in